Jeffrey W. Albers Blueprint Medicines Corp (BPMC) insider trading activity

Jeffrey W. Albers is of Blueprint Medicines Corp. Currently has a direct ownership of 157,557 shares of BPMC, which is worth approximately $14.3 Million. The most recent transaction as insider was on Mar 04, 2022, when has been sold 20,000 shares (Common Stock) at a price of $8.44 per share, resulting in proceeds of $168,800. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 158K

0% 3M change

10.5% 12M change

Total Value Held $14.3 Million

Jeffrey W. Albers Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 04 2022	BUY Exercise of conversion of derivative security	$168,800 $8.44 p/Share	20,000 Added 8.77%	208,086 Common Stock
Mar 03 2022	SELL Open market or private sale	$473,921 $60.28 p/Share	7,862 Reduced 4.01%	188,086 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	7,500 Added 3.69%	195,948 Common Stock
Nov 15 2021	SELL Open market or private sale	$3,405,300 $113.51 p/Share	30,000 Reduced 13.73%	188,448 Common Stock
Nov 15 2021	BUY Exercise of conversion of derivative security	$253,200 $8.44 p/Share	30,000 Added 12.07%	218,448 Common Stock
Nov 01 2021	SELL Open market or private sale	$575,800 $115.16 p/Share	5,000 Reduced 2.58%	188,448 Common Stock
Nov 01 2021	BUY Exercise of conversion of derivative security	$75,050 $15.01 p/Share	5,000 Added 2.52%	193,448 Common Stock
Aug 26 2021	BUY Exercise of conversion of derivative security	$29,920 $1.87 p/Share	16,000 Added 7.83%	188,448 Common Stock
Aug 19 2021	SELL Open market or private sale	$2,315,250 $92.61 p/Share	25,000 Reduced 12.66%	172,448 Common Stock
Aug 19 2021	BUY Exercise of conversion of derivative security	$211,000 $8.44 p/Share	25,000 Added 11.24%	197,448 Common Stock
May 12 2021	SELL Open market or private sale	$2,315,250 $92.61 p/Share	25,000 Reduced 12.66%	172,448 Common Stock
May 12 2021	BUY Exercise of conversion of derivative security	$211,000 $8.44 p/Share	25,000 Added 11.24%	197,448 Common Stock
Mar 04 2021	SELL Open market or private sale	$1,702,095 $89.65 p/Share	18,986 Reduced 9.92%	172,448 Common Stock
Mar 04 2021	BUY Exercise of conversion of derivative security	$88,000 $8.8 p/Share	10,000 Added 4.96%	191,434 Common Stock
Mar 01 2021	BUY Grant, award, or other acquisition	-	40,000 Added 18.06%	181,434 Common Stock
Dec 14 2020	SELL Open market or private sale	$595,900 $119.18 p/Share	5,000 Reduced 3.41%	141,434 Common Stock
Dec 14 2020	BUY Exercise of conversion of derivative security	$44,000 $8.8 p/Share	5,000 Added 3.3%	146,434 Common Stock
Nov 16 2020	SELL Open market or private sale	$1,977,000 $98.85 p/Share	20,000 Reduced 12.39%	141,434 Common Stock
Nov 16 2020	BUY Exercise of conversion of derivative security	$176,000 $8.8 p/Share	20,000 Added 11.02%	161,434 Common Stock
Oct 07 2020	SELL Open market or private sale	$495,850 $99.17 p/Share	5,000 Reduced 3.41%	141,434 Common Stock
Oct 07 2020	BUY Exercise of conversion of derivative security	$44,000 $8.8 p/Share	5,000 Added 3.3%	146,434 Common Stock

Also insider at

MGTA

Magenta Therapeutics, Inc. Healthcare

Director

KYMR

Kymera Therapeutics, Inc. Healthcare

AGLE

Aeglea BioTherapeutics, Inc. Healthcare

Director

JWA

Jeffrey W. Albers

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BPMC shares.

Notify only if

Value

Insider Trading

Get notified when an Blueprint Medicines Corp insider buys or sells BPMC shares.

Notify only if

Operation

Value

Type

News

Receive news related to Blueprint Medicines Corp

Track Activities on BPMC

Account